Hi friend,

Eight months into 2026, it’s time to take stock of the mental health market.

This Hemingway Mental Health Market Report steps back from the daily headlines to examine where the market stands, what is changing and where it might move next. We combine insights from the latest Q2 earnings with our database of investment and M&A activity, alongside the year’s most important product, clinical and regulatory developments.

There are some important signals emerging.

LifeStance is showing the commercial potential of scaled outpatient mental healthcare. BetterHelp’s cash-pay decline is accelerating, as is Talkspace’s enterprise segment. Payer rates are showing signs of improvement for some outpatient providers. Neuromodulation is having a breakout year while AI was awkwardly absent from many earnings announcements.

Meanwhile, more than $400M flowed into private companies in Q2, while M&A continued to reshape the market — including Lilly’s $3.8B bet on psychedelics and UHS’s acquisition of Talkspace.

There is plenty happening. The more interesting question is what it tells us about where the mental healthcare market is heading.

In this report, I analyse the nine most important signals from the quarter, benchmark the major public companies on growth and valuation, break down what is actually driving growth for mental-health services businesses, and outline where private capital is placing its bets in 2026 — including every major funding round and M&A deal from the quarter.

Let’s get into it.

1. Key Takeaways:

1.LifeStance is starting to show what operating leverage can deliver at scale in mental health